Twenty years ago, three brothers started a firm that would transform and elevate the business and practice of treating musculoskeletal disorders. On the occasion of their 20th anniversary, we profile Tony, Marc and John—three extraordinary investors, managers, partners, friends and mentors.
Two decades.
Which is long enough to take the measure of these three, still young, men.
The way they select companies to manage, people to fund, technologies to fight for, investments to sell and, yes, products and companies to buy back have touched every single corner of this industry.
And yet, how many people whose very health or livelihoods are due to the work of the VBs are aware of the debt they owe them?
Unlike, for example, the Michelson imprint on many Medtronic Spine products, there is no VB imprint on the thousands of implants and instruments and regulatory wins that came from Tony, Marc and John.
Eleven #1 Products and Eight Surgeon-Led Societies
Viscogliosi Brothers, LLC, today, encompasses angel investment activities, venture capital and private equity investments and a portfolio in professional service business activities like, for example, MCRA, LLC.
The common thread through all of these activities is a commitment to physicians and their patients.
Since 1999, that physician partnership focus led to 11 VB-created number-one products; 7 new market niches from first-mover products, the leading regulatory, clinical, reimbursement and quality systems advisor (MCRA) and, perhaps the crowning achievement of all since it ensures that the legacy of all this work will be continuing education, eight surgeon-led societies.
Along the way the brothers also executed a half dozen complex orthopedic structure transactions, seven transfers of PMA manufacturing and they led and managed turnarounds in four orthopedic businesses.
Of course, all of these activities have made each brother a wealthy person. Their co-investors, partners and lenders have received in excess of $2 billion.
We asked Anthony Viscogliosi to summarize what it is about his family firm that has made it so impactful over the past two decades. “We are business builders, not investment managers,” he said. “Our identity is to be the leading merchant banking family in the neuromusculoskeletal industry, based upon our unparalleled relationships, superior research based insights, access to capital, and emphasis on highest quality patient care.”
“Our vision is to leverage our expertise and knowledge and our service and technology systems to find innovative orthopedic concepts and make them sustainable technologies that can be commercialized globally.”
